The FDA has approved a tablet version of zanubrutinib for all indications, improving convenience and reducing pill burden for ...

(NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved a new tablet formulation of BRUKINSA ® (zanubrutinib) ...

As drug developers seek out novel solutions for geriatric and pediatric populations and patients with difficulty swallowing ...

Simplified storage and administration of new tablet formulation may provide greater freedom and independence for people with ...

The European Commission approved a tablet formulation of SMA treatment Evrysdi, a form aimed at giving patients more ...

Concurrent with the development of oral VK2735 ... of-enrollment-in-phase-2-venture-oral-dosing-trial-of-vk2735-tablet-formulation-in-patients-with-obesity-302411564.html SOURCE Viking ...

European Commission approves Roche’s Evrysdi tablet to treat spinal muscular atrophy: Basel Thursday, June 5, 2025, 09:00 Hrs [IST] Roche announced that the European Commission ...

The tablet formulation of zanubrutinib (Brukinsa; BeOne) is now approved for all 5 indications across several hematological ...